• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Others

    iTolerance Joins Virtual Investor `What’s Your Story` Conference

    ACCESSWIRE

    Kadimastem, iTolerance complete Pre-IND meeting for diabetes

    PR NEWSWIRE

    NLS and Kadimastem Submit Request for FDA Pre-IND Meeting for T1D

    ACCESSWIRE

    iTolerance and Kadimastem Submit Initial Targeted Engagement for CBER Products

    ACCESSWIRE

    iTolerance, Inc. to Participate at the Virtual Investor Ask the CEO Conference

    ACCESSWIRE

    iTolerance Bolsters Global Intellectual Property with Issuance of EU Patent

    ACCESSWIRE

    iTolerance, Inc. to Participate in the Virtual Investor Summer Spotlight Series

    ACCESSWIRE

    iTolerance, Inc. and Kadimastem Enter into Collaboration Agreement

    ACCESSWIRE

    iTolerance, Inc. Completes Pre-IND Meeting with U.S. FDA for Development Program as a Potential Cure for Type 1 Diabetes Without the Need for Life-long Immunosuppression

    ACCESSWIRE

    iTolerance Enters into Agreement with the DRI

    ACCESSWIRE

    iTolerance, Inc. Announces Formation of Strategic Advisory Board

    ACCESSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.